BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38064128)

  • 21. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
    Vrontis K; Economidou SC; Fotopoulos G
    Cancer Invest; 2022 Feb; 40(2):124-131. PubMed ID: 34601985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of lung large cell neuroendocrine carcinoma.
    Lo Russo G; Pusceddu S; Proto C; Macerelli M; Signorelli D; Vitali M; Ganzinelli M; Gallucci R; Zilembo N; Platania M; Buzzoni R; de Braud F; Garassino MC
    Tumour Biol; 2016 Jun; 37(6):7047-57. PubMed ID: 26943800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
    Sherman S; Rotem O; Shochat T; Zer A; Moore A; Dudnik E
    Lung Cancer; 2020 May; 143():40-46. PubMed ID: 32203769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens.
    Shimada Y; Niho S; Ishii G; Hishida T; Yoshida J; Nishimura M; Yoh K; Goto K; Ohmatsu H; Ohe Y; Nagai K
    Lung Cancer; 2012 Mar; 75(3):368-73. PubMed ID: 21920624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
    Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
    J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.
    Lowczak A; Kolasinska-Cwikla A; Osowiecka K; Glinka L; Palucki J; Rzepko R; Doboszynska A; Cwikla JB
    Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33525370
    [No Abstract]   [Full Text] [Related]  

  • 27. Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status.
    Thompson ED; Stelow EB; Mills SE; Westra WH; Bishop JA
    Am J Surg Pathol; 2016 Apr; 40(4):471-8. PubMed ID: 26735857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
    Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
    Yokota E; Iwai M; Yukawa T; Naomoto Y; Haisa M; Monobe Y; Takigawa N; Fukazawa T; Yamatsuji T
    Cancer Lett; 2024 Apr; 588():216816. PubMed ID: 38499265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors and prognostic factors for pulmonary large cell neuroendocrine carcinoma with brain metastasis.
    Chen X; Huang Y; Chen F; She H; Chen X
    Cancer Med; 2023 Feb; 12(4):4087-4099. PubMed ID: 36125491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic treatment for neuroendocrine non-small cell lung carcinoma: A cases series and a systematic review of the literature.
    Jelli B; Brandão M; Mekinda Z; Durieux V; Berghmans T
    Lung Cancer; 2023 Jul; 181():107232. PubMed ID: 37216840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment outcomes and incidence of brain metastases in pulmonary large cell neuroendocrine carcinoma.
    Zhao Y; Castonguay M; Wilke D; Xu Z; Plourde M; Mulroy L; MacNeil M; Bowes D
    Curr Probl Cancer; 2019 Feb; 43(1):54-65. PubMed ID: 30107896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
    Iida Y; Wakuda K; Kenmotsu H; Doshita K; Kodama H; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Ko R; Ono A; Naito T; Murakami H; Sugino T; Gon Y; Takahashi T
    Sci Rep; 2024 Apr; 14(1):7641. PubMed ID: 38561461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Large cell neuroendocrine carcinoma and large cell carcinomas with neuroendocrine morphology of the lung: prognosis after complete resection and systematic nodal dissection.
    Zacharias J; Nicholson AG; Ladas GP; Goldstraw P
    Ann Thorac Surg; 2003 Feb; 75(2):348-52. PubMed ID: 12607637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.
    Christopoulos P; Engel-Riedel W; Grohé C; Kropf-Sanchen C; von Pawel J; Gütz S; Kollmeier J; Eberhardt W; Ukena D; Baum V; Nimmrich I; Sieder C; Schnabel PA; Serke M; Thomas M
    Ann Oncol; 2017 Aug; 28(8):1898-1902. PubMed ID: 28535181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
    Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
    Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological diagnosis of pulmonary large cell neuroendocrine carcinoma by endobronchial ultrasound-guided transbronchial needle aspiration.
    Inage T; Nakajima T; Fujiwara T; Sakairi Y; Wada H; Suzuki H; Iwata T; Chiyo M; Nakatani Y; Yoshino I
    Thorac Cancer; 2018 Feb; 9(2):273-277. PubMed ID: 29271588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast metastasis and lung large-cell neuroendocrine carcinoma: first clinical observation.
    Papa A; Rossi L; Verrico M; Di Cristofano C; Moretti V; Strudel M; Zoratto F; Minozzi M; Tomao S
    Clin Respir J; 2017 Sep; 11(5):574-578. PubMed ID: 26365150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment with temozolomide in an elderly woman with advanced pulmonary large-cell neuroendocrine carcinoma: A case report.
    Wei J; Dong XF; Hu ZL; Tang S; Lu YF
    Medicine (Baltimore); 2018 Dec; 97(51):e13318. PubMed ID: 30572435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
    Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
    Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.